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To the Editor: In his recent in-depth review of cholesterol
crystal embolization syndrome (CCE), Meyrier1 has deli-
neated the pathogenesis, differential diagnoses, and thera-
peutic aspects of CCE. In addition to therapeutic measures of
paramount importance such as restriction of further
intravascular interventions, stop of anticoagulation, and
treatment of renal insufficiency with dialysis, we would
like to add the possibility of performing renal transplantation
in selected CCE cases with end-stage renal disease and
stable clinical course after diagnosis of CCE. We have
previously reported a patient with CCE successfully under-
going renal transplantation.2 According to the best of our
knowledge, there are so far no other published cases of the
renal transplantation after CCE-induced end-stage renal
disease.
Briefly, a 63-year-old patient with a high load of
atherosclerotic risk factors (heavy smoker, hypertension
160/80–180/100 mm Hg, severe hyperlipidemia (triglycerides
up to 500 mg/dl; low-density lipoprotein cholesterol up to
240 mg/dl)) suffered from end-stage renal disease owing to
cholesterol emboli after coronary angiography because of
symptomatic coronary artery disease in October 1997.
Within 1 week, the patient developed renal failure necessitat-
ing hemodialysis since December 1997. Smoking cessation,
effective control of blood pressure (o130/80 mm Hg), and
serum lipids (low-density lipoprotein cholesterol o100 mg/
dl) was achieved and maintained until successful renal
transplantation from a living related donor in 1998. Until
his last follow-up in May 2006, kidney function has remained
stable with a current serum creatinine level of 1.28 mg/dl,
corresponding to a calculated creatinine clearance of 60 ml/
min. Serum lipids have remained normalized with diet and
pravastatin therapy (40 mg/day) with total cholesterol levels
of about 187 mg/dl and low-density lipoprotein cholesterol
levels of about 120 mg/dl as well as normotensive blood
pressure levels have been achieved with losartan, doxazosin,
nitrendipin, and nebivolol combined antihypertensive ther-
apy, and the patient refrained from smoking.
In conclusion, secondary prevention of CCE, that is, rigid
long-term control of the underlying atherosclerotic risk
factors may enable a selected subgroup of patients with CCE
to undergo successful renal transplantation with excellent
long-term patient and graft survival.
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Kryvoshey et al.’s experience1 with renal transplantation to
treat end-stage renal disease following cholesterol crystal
embolism to the kidney is quite interesting. That renal
replacement was not complicated by relapse of cholesterol
crystal embolism on the transplant confirms the interest of
stabilizing atherosclerotic plaques with statins, as already
shown by Scolari et al.2 However, patients with massive
cholesterol crystal embolism do not die from renal failure
but from vital organ injury, such as mesenteric and
pancreatic ischemia. From this standpoint, the writers of
this letter confirm the essential role of preventing
cholesterol crystal embolism in patients at risk, that is,
lifelong smokers with lipid disorders and widespread
atherosclerosis.
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To the Editor: We were interested in the recent paper by
Kanderian and Francis1 in which they review hypothetical
mechanisms contributing to the increase in serum troponin
concentrations observed in chronic kidney disease (CKD).
The work of Diris et al.,2 who demonstrated fragments of the
cardiac troponin T (cTnT) molecule ranging in size from 8 to
25 kDa in hemodialysis patients, is discussed. It is suggested
Kidney International (2006) 70, 1523–1527 1525
l e t t e r t o t h e e d i t o r
